US Drug Developers Antegrin, Cascadia Merge to Form Indalo Therapeutics.
19 October 2016 - St. Louis, Missouri-based drug discovery and development company Antegrin Therapeutics has merged with Seattle, Washington-based drug company Cascadia Therapeutics to form novel therapy biotechnology company Indalo Therapeutics, the company said.
Financial terms of the deal were not disclosed.
The new organisation unites Antegrin's portfolio of small-molecule integrin antagonists with the drug-development expertise, seasoned executive experience, and track record of Cascadia.
Indalo Therapeutics is a biotechnology company dedicated to developing novel treatments for fibrotic diseases.
The company was founded to exploit the therapeutic potential of RGD-binding integrin antagonists by leveraging groundbreaking discoveries on the role of these integrins in the pathogenesis of fibrosis.
Its portfolio of integrin antagonists has potential utility in a broad range of fibrotic diseases. The company has received funding from BioGenerator, Missouri Technology Corp.,iSelect Fund, and other investors.
Antegrin Therapeutics, a drug discovery and development company, develops therapies and compounds for fibrotic diseases. The company was founded in 2014.
Target: Antegrin Therapeutics
Buyer: Cascadia Therapeutics
Deal size in USD:
Buyer advisor: , ,
Comment: Merged company is called Indalo Therapeutics
|Printer friendly Cite/link Email Feedback|
|Publication:||M & A Navigator|
|Date:||Oct 19, 2016|
|Previous Article:||Dungarvin Acquires Indiana Home Healthcare Company.|
|Next Article:||Deal snapshot: VAIL RESORTS CLOSES USD 1.056BN ACQUISITION OF CANADIAN MOUNTAIN RESORT OPERATOR WHISTLER BLACKCOMB.|